December 8th, 2021 | 14:02 CET
Valneva, Novavax, Manganese X Energy: The new pandemic fighters?
Table of contents:
"[...] We believe that these findings could be of great benefit in protecting at-risk patients. [...]" David Elsley, CEO, Cardiol Therapeutics
Manganese X Energy: Newcomer with an interesting mix
The share of Manganese X Energy Corp. has been listed on the Frankfurt Stock Exchange for a relatively short time and is probably only known to a few investors. However, the diversified business model offers a lot of fantasy at an attractive valuation. The market capitalization of the Canadian Company is currently a manageable CAD 36 million. Manganese wants to contribute to the fight against the Corona pandemic with a new type of air purification. To this end, Disruptive Battery Corp, a wholly-owned subsidiary of Manganese X, plans to buy a patent for the circulation of air disinfectants and develop products based on it. The invention represents a method for reducing microbial contamination using HVAC cleaning systems inside a building. The field of application is vast and should also provide significant sales opportunities once the battle against COVID-19 is won.
In addition, Manganese X is active in other exciting industries. Among other things, it is currently the only publicly-traded Company in North America seeking to commercialize a prospective manganese deposit. The 1,228-hectare Battery Hill metal project is located in New Brunswick, just 12 km from the US border - a key sales market. The NI 43-101 technical report is already available, indicating an estimated 2.5% manganese FE resource of approximately 60 million tonnes. In addition, Manganese X owns a 2,568-hectare copper-nickel-cobalt property in Quebec. Both projects are promising.
Valneva: Criticism from Great Britain
Valneva is looking to shake up the vaccine market dominated by BioNTech and Moderna with a so-called dead vaccine. After initial positive study results and the start of the approval test had caused euphoria among investors, the mood has changed in recent days. A study in the UK last week caused uncertainty. In this study, the booster effect of various vaccines was tested. On this basis, the British have increased their vaccine stocks and ordered 54 million doses from BioNTech and 60 million doses from Moderna. Valneva had performed less well in the booster study. The Company commented on this in a detailed statement.
"The setting of the study leads us to believe that COV-Boost is not indicative of the use of VLA2001 as a booster in a real-world setting. The threshold for protective antibodies has not yet been established, so a relative increase in antibody levels should not be considered an indicator of efficacy," said Juan Carlos Jaramillo, chief medical officer of Valneva. "I agree with Professor Faust's comments that the data describe the immune response at 28 days, not the efficacy of the vaccine and that the relationship between this response and long-term protection is poorly understood, especially since several studies have shown that longer periods between vaccine doses improve the immune response." Investors, however, were not yet reassured by this. Perhaps a new analysis by the editors of researchanalyst.com, who took a closer look at the stock, will do just that.
Is Novavax winning the race against Valneva?
No inactivated vaccine has yet received final approval, but it appears Novavax is winning the race against Valneva. The Company filed for approval of its vaccine in mid-November and expects approval in a few weeks. Novavax reported 90% efficacy and has already signed supply contracts for 100 million doses with the European Union for 2022. There is also an option for another 100 million doses in 2023. Inactivated vaccines are also expected to bring new momentum to vaccination campaigns in the United States and Europe. They should help convince vaccination opponents to vaccinate. Many vaccination opponents argue that the vaccines from BioNTech and Moderna are based on the relatively new mRNA technology, which has not yet been sufficiently researched.
The orders from the EU and the UK show that the fight against COVID-19 will keep us busy until at least 2023. Accordingly, stocks from this sector remain interesting. Novavax, Valneva and Manganese X are unlikely to be too late to generate significant sales around the Corona pandemic.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.